Clinical Trial Update: Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Zevalin-containing nonmyeloablative conditioning for stem cell transplantation in leukemia and lymphoma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-05-05